Peptide Systems

Executive Summary

Peptide Systems, founded in 1995 and headquartered in San Diego, is a private company specializing in the supply of high-purity research peptides, small molecules, and drug delivery solutions. Serving primarily the research community, the company differentiates itself through third-party certified Certificates of Analysis (COAs) from ISO-certified laboratories, positioning itself as a trusted source for quality research materials. With nearly three decades of operational history, Peptide Systems has established a niche in the competitive peptide supply market, focusing on reliability and quality assurance. However, the company operates in a mature segment with limited public catalysts, as it does not pursue drug development itself. Growth opportunities may arise from expanding its product portfolio into novel peptides, increasing demand for research tools in areas like GLP-1 agonists and cell-penetrating peptides, or forming strategic partnerships with pharmaceutical companies seeking validated research-grade materials. The company remains privately held with no disclosed funding rounds or valuation, suggesting a slow but steady business model. Its long-standing presence and emphasis on quality provide a stable foundation, but significant near-term inflection points are not evident.

Upcoming Catalysts (preview)

• Q3 2026Expansion into GLP-1 and obesity-related research peptides70% success
• TBDStrategic partnership with a mid-tier biotech for custom peptide synthesis50% success